Brigitte C. Widemann
#176,389
Most Influential Person Now
German-American pediatric oncologist
Brigitte C. Widemann's AcademicInfluence.com Rankings
Brigitte C. Widemannmedical Degrees
Medical
#3645
World Rank
#4136
Historical Rank
#549
USA Rank
Oncology
#259
World Rank
#267
Historical Rank
#27
USA Rank
Download Badge
Medical
Why Is Brigitte C. Widemann Influential?
(Suggest an Edit or Addition)According to Wikipedia, Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.
Brigitte C. Widemann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Understanding and managing methotrexate nephrotoxicity. (2006) (589)
- Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. (2016) (418)
- Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. (2017) (341)
- Low-intensity therapy in adults with Burkitt's lymphoma. (2013) (272)
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. (2013) (268)
- High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma (2004) (260)
- Selumetinib in Children with Inoperable Plexiform Neurofibromas. (2020) (231)
- Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. (2017) (221)
- Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. (2008) (195)
- Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. (2012) (177)
- NF1 plexiform neurofibroma growth rate by volumetric MRI (2007) (160)
- Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. (2006) (140)
- Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. (2003) (138)
- Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma (2013) (124)
- Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. (2010) (116)
- Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. (2008) (113)
- Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. (2016) (112)
- Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors (2009) (111)
- Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. (1997) (110)
- Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. (2015) (107)
- Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia (2012) (106)
- Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2 (2012) (105)
- A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report (2012) (103)
- A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. (2010) (98)
- Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum (2018) (98)
- Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group (2006) (97)
- Recommendations for imaging tumor response in neurofibromatosis clinical trials (2013) (96)
- Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1 (2012) (94)
- Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. (2012) (91)
- Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance (2017) (88)
- Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. (2014) (85)
- Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors (2014) (85)
- Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. (2004) (83)
- Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies (2017) (82)
- MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research (2016) (77)
- The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas (2017) (73)
- Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas (2014) (73)
- Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. (2016) (73)
- Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas (2009) (73)
- Sirolimus for non‐progressive NF1‐associated plexiform neurofibromas: An NF clinical trials consortium phase II study (2014) (72)
- Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. (2018) (72)
- Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. (2018) (71)
- Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future (2017) (71)
- Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. (2007) (71)
- Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables. (2012) (70)
- Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas (2013) (69)
- Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social‐emotional functioning, and quality of life (2015) (65)
- Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2 (2009) (65)
- The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors (2018) (65)
- Sorafenib and sunitinib. (2009) (62)
- Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. (2000) (62)
- Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group (2015) (60)
- Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High‐Dose Methotrexate Therapy (2014) (60)
- A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors (2006) (59)
- Carboxypeptidase‐G2 rescue in a patient with high dose methotrexate‐induced nephrotoxicity (1995) (57)
- Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging (2012) (55)
- Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias (2016) (53)
- Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. (2004) (53)
- Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas (2016) (52)
- 18‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST) (2013) (51)
- Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define pre-malignant neurofibromatosis type 1-associated atypical neurofibromas. (2019) (51)
- Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome. (2019) (48)
- Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1 (2018) (46)
- Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. (2008) (46)
- A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS–FLI1 fusion transcript (2017) (45)
- Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. (1996) (45)
- Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1: Multidisciplinary Recommendations for Care. (2017) (44)
- Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group (2015) (44)
- Validity, specificity, feasibility and acceptability of a brief pediatric distress thermometer in outpatient clinics (2017) (44)
- Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. (2005) (44)
- Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors (2015) (43)
- Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient. (2014) (43)
- SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors (2017) (42)
- Dihydrofolate reductase enzyme inhibition assay for plasma methotrexate determination using a 96-well microplate reader. (1999) (41)
- Acceptance and commitment therapy in youth with neurofibromatosis type 1 (NF1) and chronic pain and their parents: A pilot study of feasibility and preliminary efficacy (2016) (40)
- Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas (2009) (39)
- Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). (2014) (39)
- Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer (2016) (39)
- Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group (2010) (36)
- Advancing RAS/RASopathy therapies: An NCI‐sponsored intramural and extramural collaboration for the study of RASopathies (2019) (36)
- Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 (2018) (35)
- The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression (2008) (35)
- A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. (2005) (34)
- Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors (2001) (34)
- Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016) (2019) (33)
- A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group (2018) (33)
- Achieving consensus for clinical trials (2013) (33)
- A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors (2008) (33)
- Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report. (2015) (33)
- Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study. (2005) (32)
- The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (TomudexTM) in a nonhuman primate model (1999) (32)
- SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). (2016) (31)
- SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). (2013) (30)
- NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas (2021) (30)
- Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. (2014) (30)
- A phase I trial and pharmacokinetic study of a 24‐hour infusion of trabectedin (Yondelis®, ET‐743) in children and adolescents with relapsed or refractory solid tumors (2012) (29)
- Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma (2015) (29)
- Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1 (2013) (29)
- Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging (2014) (29)
- Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial (2021) (28)
- Genetic Modifiers of Neurofibromatosis Type 1-Associated Café-au-Lait Macule Count Identified Using Multi-platform Analysis (2014) (28)
- Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. (2020) (28)
- The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway (2016) (28)
- The Bioavailability of Oral Methotrexate in Children with Inflammatory Bowel Disease (2005) (27)
- Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group (2011) (27)
- Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023) (2020) (27)
- Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101 (2004) (26)
- Current status of MEK inhibitors in the treatment of plexiform neurofibromas (2020) (26)
- SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). (2016) (26)
- Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis (2013) (25)
- Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study (2001) (25)
- Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. (1999) (24)
- Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti‐angiogenic therapy: A report from the children's oncology group phase I consortium (2015) (24)
- Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib (2017) (23)
- Cephalometry in adults and children with neurofibromatosis type 1: Implications for the pathogenesis of sphenoid wing dysplasia and the "NF1 facies". (2015) (23)
- Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas. (2013) (23)
- A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study. (2001) (20)
- Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. (2009) (20)
- Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. (2020) (19)
- The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates (2012) (19)
- Conclusions and future directions for the REiNS International Collaboration (2013) (19)
- Evaluation and Treatment of Fever in the Non‐Neutropenic Child With Cancer (2003) (19)
- Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. (2009) (18)
- Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study (2021) (18)
- CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies (2014) (18)
- Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors (2009) (18)
- Identifying Symptoms of Distress in Youth Living with Neurofibromatosis Type 1 (NF1) (2018) (17)
- Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters (2019) (17)
- Cushing Disease in a patient with Multiple Endocrine Neoplasia type 2B. (2017) (17)
- The Relationship Between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1 (2018) (17)
- Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors (2015) (16)
- Current status and recommendations for biomarkers and biobanking in neurofibromatosis (2016) (16)
- The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. (2020) (16)
- NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (2018) (16)
- Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma. (2009) (15)
- Update from the 2013 international neurofibromatosis conference (2014) (15)
- (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. (2012) (14)
- Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods. (2018) (14)
- Pediatric phase I trial design using maximum target inhibition as the primary endpoint. (2010) (14)
- Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years (2018) (14)
- Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B (2018) (14)
- Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute. (2011) (14)
- Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy (2015) (13)
- 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis (2018) (13)
- Malignant Peripheral Nerve Sheath Tumors: Prognostic and Diagnostic Markers and Therapeutic Targets (2012) (13)
- A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. (2020) (12)
- A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor (2019) (12)
- Bone mineral density in children and young adults with neurofibromatosis type 1. (2012) (12)
- Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. (2018) (12)
- Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas (2020) (11)
- Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials (2011) (11)
- Attitudes About Internet Support Groups Among Adolescents and Young Adults with Neurofibromatosis Type 1 and their Parents (2014) (11)
- Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer (2021) (11)
- Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1 (2016) (10)
- SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma (2020) (10)
- SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors (2017) (10)
- Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN). (2020) (10)
- Outcome of recurrent osteosarcoma patients enrolled in seven phase II trials through CCG, POG, and COG: Learning from the past to move forward. (2015) (9)
- Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates (2016) (9)
- Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta). (2013) (9)
- Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas (2020) (9)
- PET‐guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1 (2013) (9)
- Creating a comprehensive research strategy for cutaneous neurofibromas (2018) (9)
- Clinical trial design for cutaneous neurofibromas (2018) (9)
- Age-Dependent Changes in Sirolimus Metabolite Formation in Patients With Neurofibromatosis Type 1 (2015) (9)
- Chordoma: Current status, problems, and future directions. (2021) (8)
- Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1 (2021) (8)
- Phase II study of the mTOR inhibitor sirolimus for nonprogressive NF1-associated plexiform neurofibromas: A Neurofibromatosis Consortium study. (2010) (8)
- Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. (2014) (8)
- Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. (2011) (8)
- Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates (2001) (8)
- HIGH GRADE GLIOMAS (2012) (8)
- Radiation Therapy in Management of Sporadic and Neurofibromatosis Type 1 (NF1) Associated Malignant Peripheral Nerve Sheath Tumors (MPNST) (2012) (8)
- Phase I trial of the epothilone B analog BMS-247550 (ixabepilone) in children with refractory solid tumors (2005) (8)
- A molecular basis for neurofibroma-associated skeletal manifestations in NF1 (2020) (8)
- Phase I trial and pharmacokinetic (PK) study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors. (2004) (7)
- From process to progress—2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis (2019) (7)
- Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model (2015) (7)
- HISTOPATHOLOGIC EVALUATION OF ATYPICAL NEUROFIBROMATOUS TUMORS AND THEIR TRANSFORMATION INTO MALIGNANT PERIPHERAL NERVE SHEATH TUMOR IN NEUROFIBROMATOSIS 1 PATIENTS – A CONSENSUS OVERVIEW (2017) (7)
- A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial. (2014) (7)
- SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST). (2014) (7)
- A phase I trial of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in hormone-receptor positive metastatic breast cancer. (2004) (7)
- Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity. (2012) (7)
- Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622). (2021) (7)
- Translational/Clinical Studies in Children and Adults with Neurofibromatosis Type 1 (2012) (7)
- Cediranib phase‐II study in children with metastatic alveolar soft‐part sarcoma (ASPS) (2019) (7)
- MEK Inhibitors for Neurofibromatosis Type 1 Manifestations: Clinical Evidence and Consensus. (2022) (7)
- Proceedings of the fifth international RASopathies symposium: When development and cancer intersect (2018) (7)
- First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics (2019) (6)
- Clinical trial design in neurofibromatosis type 1 as a model for other tumor predisposition syndromes. (2020) (6)
- Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions. (2017) (6)
- Phase I study of pexidartinib (PLX3397) in children with refractory leukemias and solid tumors including neurofibromatosis type I (NF1) related plexiform neurofibromas (PN). (2017) (6)
- Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS). (2018) (6)
- Practical considerations for the administration of glucarpidase in high‐dose methotrexate (HDMTX) induced renal dysfunction (2015) (6)
- Selumetinib in Plexiform Neurofibromas. (2017) (5)
- Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma (2019) (5)
- Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum (2018) (5)
- A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (guadecitabine), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer. (2018) (5)
- NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) (2018) (5)
- Phase I trial of oral ABT-751 in pediatric patients: Preliminary evidence of activity in neuroblastoma (NBL) (2005) (5)
- Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children’s Oncology Group (2008) (5)
- Developing therapies for rare tumors: opportunities, challenges and progress (2016) (4)
- Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo (2021) (4)
- Sirolimus for progressive neurofibromatosis type 1 – associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study (2015) (4)
- A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer. (2020) (4)
- A phase II trial of vandetanib (ZD6474) in children and adults with wild-type gastrointestinal stromal tumors. (2016) (4)
- Sorafenib and Sunitinib (Oncologist (2009) 14 (800-805) DOI: 10.1634/theoncologist.2009-0088) (2009) (4)
- The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates (2011) (4)
- Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer (2012) (4)
- Carboxypeptidase-G2 (CPDG2) and leucovorin (LV) rescue with and without addition of thymidine (Thd) for high-dose methotrexate (HDMTX) induced renal dysfunction (2005) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- Randomized trial and pharmacokinetic study of pegfilgrastim vs. filgrastim in children and young adults with newly diagnosed sarcoma treated with dose intensive chemotherapy. (2006) (4)
- Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. (2014) (4)
- Genome‐wide association study of café‐au‐lait macule number in neurofibromatosis type 1 (2020) (3)
- Are Some Randomized Clinical Trials Impossible? (2020) (3)
- Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials. (2021) (3)
- Merlin PAKs a punch. (2004) (3)
- Plasma and cerebrospinal fluid pharmacokinetics of selumetinib in non-human primates (NHP). (2017) (3)
- Acceptance and commitment therapy for adolescents and adults with neurofibromatosis Type 1, plexiform neurofibromas, and chronic pain: Results of a randomized controlled trial (2021) (3)
- Atypical neurofibromas in neurofibromatosis 1 (NF1): Clinical, imaging and pathologic characteristics. (2016) (3)
- Management of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. (2022) (3)
- Consensus for NF clinical trials (2016) (3)
- NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY (2018) (3)
- Molecular mechanism(s) of resistance to vandetanib in medullary thyroid carcinoma. (2020) (2)
- Immunogenicity and safety of glucarpidase for methotrexate toxicity. (2014) (2)
- Abstract 2937: An EGFR-STAT3 pathway promotes NF1 peripheral nerve tumorigenesis and transformation (2012) (2)
- Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment (2022) (2)
- The pharmacokinetics (PK) and pharmacodynamics (PD) of ABT-751 in children with recurrent neuroblastoma or other solid tumors (2007) (2)
- Using a lower dose of glucarpidase to reduce plasma levels of methotrexate. (2013) (2)
- Pediatric phase I trial and pharmacokinetic study of ‘Tomudex’ (Ralitrexed) (1999) (2)
- Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofibroma At Risk for Developing Tumor-Related Morbidity. (2022) (2)
- Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies (2021) (2)
- Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors (2021) (2)
- Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinoma. (2021) (2)
- Immune checkpoint inhibitors for refractory childhood cancers. (2019) (2)
- Peripheral Neuropathy (PN) in Individuals with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibromas (PNF) (P6.093) (2014) (2)
- Robotic Nerve Sheath Tumor Resection With Intraoperative Neuromonitoring: Case Series and Systematic Review (2021) (2)
- EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
- Automatic lesion detection and volume measurement in MR imaging of plexiform neurofibromas (2002) (2)
- Pediatric phase I trial and pharmacokinetic study of P-glycoprotein inhibitor, tariquidar, in combination with doxorubicin, vinorelbine or docetaxel (2004) (2)
- Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET (2021) (1)
- Comparative Genomic Analysis of NF1-Associated Atypical Neurofibromas (ANF) and Malignant Peripheral Nerve Sheath Tumors (MPNST) (2016) (1)
- Impact of MEK inhibitor therapy on neurocognition in neurofibromatosis type 1 (2020) (1)
- The Perceived Influence of Neurofibromatosis Type 1(NF1) on the Parents’ Relationship (2023) (1)
- Abstract 1411: Plasma and cerebrospinal fluid pharmacokinetics of tocilizumab in a nonhuman primate model (2016) (1)
- US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions (2017) (1)
- RARE-07. THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1 (2018) (1)
- Reply to: Glucarpidase for the Treatment of Methotrexate‐Induced Renal Dysfunction and Delayed Methotrexate Excretion (2016) (1)
- Reply to P.A. Meyers et al (2011) (1)
- Editorial: Special issue on rare cancers. (2021) (1)
- Pharmacokinetics and Tolerability of Etoposide in Newly Diagnosed Lymphoma Patients with Hepatic Impairment (2014) (1)
- Atypical Neurofibromas in NF1: Clinical, Imaging and Pathology Characteristics. NF (2016) (1)
- Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC) (2022) (1)
- Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1-Erratum. (2016) (1)
- Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial (2019) (1)
- Orbital/Peri-Orbital Plexiform Neurofibromas in Children with Neurofibromatosis type 1: Multi-disciplinary Recommendations for Care (2016) (1)
- Pharmacokinetics and tolerability of doxorubicin in newly diagnosed lymphoma patients with hepatic impairment. (2014) (1)
- acute promyelocytic leukemia or lymphoma and adolescents with refractory or relapsed acute leukemia, including Phase 1 trial and pharmacokinetic study of arsenic trioxide in children (2013) (1)
- Pediatric phase I trial and pharmacokinetic study of P-glycoprotein inhibitor, tariquidar, in combination with doxorubicin, vinorelbine or docetaxel. (2004) (1)
- RESPONSE: Re: Treatment of Accidental Intrathecal Methotrexate Overdose (2005) (1)
- Cell-free DNA ultra-low-pass whole genome sequencing distinguishes malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion (2021) (1)
- Plasma and cerebrospinal fluid pharmacokinetics of doxil after intravenous administration in adults with primary CNS lymphoma. (2017) (1)
- Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). (2016) (1)
- Pediatric adrenocortical carcinoma (2022) (1)
- Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the Children's Oncology Group Phase i Consortium (2016) (1)
- Abstract PR07: Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) (2019) (1)
- EXTH-65. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS COMPARISON OF BRAF AND MEK INHIBITORS FOLLOWING SINGLE AND EXTENDED ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL (2019) (0)
- Effect of local therapies on survival in patients with metastatic adrenocortical carcinoma. (2020) (0)
- Abstract 461: Identifying potential immunotherapeutic targets on malignant peripheral nerve sheath tumors via surfaceomic profiling (2020) (0)
- Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor (2022) (0)
- Abstract 805: Intra-tumoral pharmacodynamics of selumetinib in serial biopsies from patients with neurofibroma (2020) (0)
- Pulmonary Function in Patients with Multiple Endocrine Neoplasia 2B (MEN2B). (2020) (0)
- Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 (2018) (0)
- #645 Comparison o cerebrospinal fluid (CSF) pharmacokinetics (PK) of methotrexate (MTX) in non‐human primates after intraventricular and intralumbar adimistration with and without probencid (1998) (0)
- Phase I trial and pharmacokinetic (PK) study of satraplatin in children and young adults with refractory solid tumors including brain tumors. (2013) (0)
- Study of ABT-751 , an Orally BioavailableTubulin Inhibitor , Administered Daily for 21 Days Every 28 Days in Pediatric Patients with SolidTumors (2008) (0)
- Abstract 3374: Effect of bevacizumab and dexamethasone on plasma ultrafiltrate (UF) and cerebrospinal fluid (CSF) pharmacokinetics (PKs) of carboplatin in a non-human primate (NHP) model.: (2013) (0)
- Abstract 3356: Comparative plasma and cerebrospinal (CSF) pharmacokinetics (PK) of vincristine sulfate standard preparation (VCR) and vincristine sulfate liposomes injection (VSLI) in a non-human primate (NHP) model. (2013) (0)
- Abstract 1456: Identifying early genetic steps in malignant transformation of neurofibromatosis type 1- associated plexiform neurofibromas (2017) (0)
- Abstract 5038: Comparison of the dose response of malignant peripheral nerve sheath tumor in vitro growth inhibition of 30 drugs to reported Cmax values (2017) (0)
- #217 Evaluation and treatment of the febrile, non-neutropenic pediatric oncology patient (1999) (0)
- [REiNS] NF Clinical Trials - REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead. (2021) (0)
- Phase I T rial a nd P harmacokinetic S tudy o f B MS-247550, a n Epothilone B A nalog, A dministered I ntravenously o n a D aily Schedule f or F ive D ays (2003) (0)
- MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors (2023) (0)
- Demographic and Disease-Related Predictors of Socioemotional Development in Children with Neurofibromatosis Type 1 and Plexiform Neurofibromas: An Exploratory Study (2022) (0)
- Abstract A46: Charting the synthetic lethality landscape in pediatric cancer to advance whole-exome precision-based treatments (2020) (0)
- INNV-04. A MULTI-INSTITUTIONAL CLINICAL AND MRI REPOSITORY OF NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PERIPHERAL NERVE SHEATH TUMORS (2021) (0)
- Prevalence of palliative care consultations in phase I pediatric oncology trials. (2018) (0)
- Abstract 5040: The plasma and cerebrospinal fluid pharmacokinetics of pegylated liposomal doxorubicin after intravenous administration in non-human primates (2017) (0)
- Characteristics and outcome of patients (pts) enrolled on phase I trials: A report from the Pediatric Oncology Branch, NCI (2007) (0)
- Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: A Multicenter Project With 3 Clinical Trials (2006) (0)
- Bevacizumab Impact on Hearing Loss Due to Neurofibromatosis Type 2 Associated Vestibular Schwannomas and Associated Biomarkers (S34.004) (2016) (0)
- Natural history study for children and adults with rare solid tumors. (2022) (0)
- Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13, 2001 at the Schloss Reisensburg, Günzburg an der donau. (2002) (0)
- Abstract 3898: Loss of polycomb repressive complex 2 activates HOXB8 and remodels super enhancers in malignant peripheral nerve sheath tumors (2020) (0)
- Surgery and Proton Radiation Therapy for Pediatric Base of Skull Chordomas: Long-term Clinical Outcomes for 204 patients. (2023) (0)
- Long-Term Safety and Efficacy of Selumetinib in Children with Neurofibromatosis Type 1 on a Phase 1/2 Trial for Inoperable Plexiform Neurofibromas. (2023) (0)
- Development of Targeted Therapies for Neurofibromatosis Type 1 (NF1) Related Tumors (2010) (0)
- Reliability of HandheldDynamometry toMeasure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2 (0)
- Abstract 4199: Developing therapies for rare tumors: Using mouse models of malignant peripheral nerve sheath tumors to complement rare human samples in drug screens (2015) (0)
- ConsensusRecommendations for Current Treatments and Accelerating Clinical Trials for Patients With Neurofibromatosis Type 2 (2011) (0)
- A molecular basis for neurofibroma-associated skeletal manifestations in NF1 (2020) (0)
- Abstract 3599: The plasma and cerebrospinal fluid pharmacokinetics of satraplatin after intravenous administration in non-human primates (2010) (0)
- Tumor Doubling Time Using CT Volumetric Segmentation in Metastatic Adrenocortical Carcinoma (2021) (0)
- P0607 THE ORAL BIOAVAILABILITY OF METHOTREXATE IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2004) (0)
- Longitudinal association between executive function and academic achievement in children with neurofibromatosis type 1 and plexiform neurofibromas. (2023) (0)
- Systematic review of pediatric oncology phase I trials: Toxicity and outcomes in the era of targeted therapies. (2018) (0)
- Abstract A2: Using plexiform neurofibroma preclinical therapeutics to help guide clinical trials (2014) (0)
- Abstract 4882: Genomic mechanisms of disease progression in pediatric medullary thyroid cancer (MTC) (2017) (0)
- Malignant Peripheral Nerve Sheath Tumor (2020) (0)
- Neurofibromatosis Clinical Trials—REiNS Collaboration 2020 Recommendations (2021) (0)
- TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1 (2019) (0)
- Pediatric phase I trial design using a pharmacodynamic marker as the primary endpoint (2008) (0)
- Abstract 4512: My Pediatric and Adult Rare Tumor Network (MyPART): integrating longitudinal, clinical, molecular, and patient-reported outcomes for rare tumors (2023) (0)
- Fascicle Sparing Capsular Resections of Atypical Neurofibromas in Neurofibromatosis 1 (2019) (0)
- Early detection of transformation of plexiform neurofibromas to malignant peripheral nerve sheath tumors in neurofibromatosis type 1. (2015) (0)
- NIMG-08. A MULTI-CENTER RADIOMICS-BASED MODEL TO DIFFERENTIATE BETWEEN NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (2021) (0)
- Outcome of Patients With Malignant Peripheral Nerve Sheath Tumors Enrolled on Sarcoma Alliance for Research Through Collaboration (SARC) Phase II Trials. (2023) (0)
- Abstract 3596: Comparison of intravenous microdialysis sampling to standard blood sampling to determine free etoposide exposure in non-human primates (2010) (0)
- Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning (2021) (0)
- EXTH-102. PLASMA AND CEREBROSPINAL FLUID (CSF) PHARMACOKINETICS (PK) OF MIRDAMETINIB IN A NON-HUMAN PRIMATE (NHP) MODEL (2022) (0)
- Table of Contents, Volume 170A, Number 8, August 2016 (2016) (0)
- EXTH-64. COMPARISON OF PANOBINOSTAT CSF PENETRATION WITH CNS PENETRATION FOLLOWING SYSTEMIC ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL (2021) (0)
- PMON127 Neuroendocrine Tumor of the Spinal Cord- A Case Report of Rare Endocrine Tumor Presentation (2022) (0)
- Poster 24: Joint Range of Motion (ROM) in Persons with Neurofibromatosis Type 1 (NF 1) (2009) (0)
- Imaging of plexiform neurofibromas in neurofibromatosis type 1 (2013) (0)
- Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial (2021) (0)
- A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma. (2022) (0)
- REiNS: Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. (2021) (0)
- Abstract 3882: Clinical exome and transcriptome sequencing for identification of actionable cancer targets: A pilot study for children and young adults with relapsed or refractory solid tumors (2015) (0)
- Comparison of a STIR- and T1-based radiomics model to differentiate between plexiform neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 (NF1) (S17.010) (2023) (0)
- NIMG-16. COMPARISON OF A STIR- AND T1-WEIGHTED-BASED RADIOMICS MODEL TO DIFFERENTIATE BETWEEN PLEXIFORM NEUROFIBROMAS AND MALIGNANT PERIPHERAL NERVE SHEATH TUMORS IN NEUROFIBROMATOSIS TYPE 1 (NF1) (2022) (0)
- Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model (2011) (0)
- Loss of PRC2 Enforces a Mesenchymal Neural Crest Stem Cell Phenotype in NF1-Deficient Cancer Through Activation of Core Transcription Factors (2021) (0)
- Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. (2017) (0)
- Abstract A5: Phase I trial and pharmacokinetic study of cediranib in children with recurrent or refractory solid tumors (2009) (0)
- Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity. (2022) (0)
- HIGH GRADE GLIOMAS AND DIPG (2014) (0)
- Diagnosis and Management of Benign Nerve Sheath Tumors in NF1: Evolution from Plexiform to Atypical Neurofibroma and Novel Treatment Approaches (2020) (0)
- Abstract IA16: Natural history of peripheral nerve sheath tumors in NF1: Identification and characterization of malignant precursor lesions (2018) (0)
- Abstract IA33: Development of effective therapies for neurofibromatosis type 1 and other pediatric RAS-driven tumors (2020) (0)
- EXTH-100. EVALUATION OF PANOBINOSTAT PLASMA AND CEREBROSPINAL FLUID (CSF) PHARMACOKINETIC PROFILE FOLLOWING ADMINISTRATION OF THE CAPSULE FORMULATION FARYDAK® IN A NON-HUMAN (NHP) PRIMATE PRECLINICAL MODEL (2022) (0)
- Radiographic tumor response in pediatric patients with newly diagnosed localized (LOC) or metastatic (MET) Ewing’s sarcoma (EWS) following neoadjuvant chemotherapy (2007) (0)
- SUN-341 A Natural History Study for Rare Tumors: An Avenue for Discovering and Understanding Endocrine Cancers (2019) (0)
- A Phase 1Study of ABT-751, an Orally BioavailableTubulin Inhibitor, Administered Daily for 7 Days Every 21Days in Pediatric Patients with Solid Tumors (2006) (0)
- Outcomes of children with hereditary medullary thyroid carcinoma (MTC) treated with vandetanib. (2017) (0)
- Reporting of Racial and Ethnic Minority Representation in Early Phase Pediatric Oncology Clinical Trials. (2022) (0)
- Abstract 2943: Severe hepatotoxicity of mithramycin therapy caused by altering expression of hepatocellular bile transporters (2019) (0)
- Patient reported outcomes in adult patients with neuroendocrine neoplasms. (2022) (0)
- Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas. (2022) (0)
- Patient-Derived Organoids and Their Potential for Precision Medicine in Neuroendocrine Tumors (2023) (0)
- Advances, challenges and progress in pediatric hematology and oncology. (2023) (0)
- Propranolol and Somatostatin Agonist Therapy Resulting in Symptom Improvement and Stabilization of von Hippel-Lindau-Associated Hemangioblastoma: A Case Report (2021) (0)
This paper list is powered by the following services:
Other Resources About Brigitte C. Widemann
What Schools Are Affiliated With Brigitte C. Widemann?
Brigitte C. Widemann is affiliated with the following schools:
